Literature DB >> 15142400

Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.

Thomas E Brown1.   

Abstract

Atomoxetine and stimulants have both been demonstrated effective as single agents for treatment of attention deficit hyperactivity disorder in children, adolescents, and adults. However, attention deficit hyperactivity disorder symptoms in some patients do not respond adequately to single-agent treatment with these medications, each of which is presumed to impact dopaminergic and noradrenergic networks by alternative mechanisms in different ratios. Four cases are presented to illustrate how atomoxetine and stimulants can be utilized effectively in combination to extend duration of symptom relief without intolerable side effects or to alleviate a wider range of impairing symptoms than either agent alone. This combined pharmacotherapy appears effective for some patients who do not respond adequately to monotherapy, but because there is virtually no research to establish safety and effectiveness of such strategies, careful monitoring is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142400     DOI: 10.1089/104454604773840571

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  15 in total

1.  A review of long-acting medications for ADHD in Canada.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-11

2.  Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.

Authors:  Amanda Jacques
Journal:  Can Pharm J (Ott)       Date:  2012-09

Review 3.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 4.  Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.

Authors:  Suyash Prasad; Chris Steer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.

Authors:  Roxann C Harvey; Chloe J Jordan; David H Tassin; Kayla R Moody; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2013-01-31       Impact factor: 3.332

6.  An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

Authors:  Paul Hammerness; Anna Georgiopoulos; Robert L Doyle; Linsey Utzinger; Mary Schillinger; Marykate Martelon; Kerry Brodziak; Joseph Biederman; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

7.  Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Thomas J Spencer; Michael Greenbaum; Lawrence D Ginsberg; William Rory Murphy
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

8.  An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Authors:  Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

Review 9.  A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Authors:  Tamás Treuer; Susan Shur-Fen Gau; Luis Méndez; William Montgomery; Julie A Monk; Murat Altin; Shenghu Wu; Chaucer C H Lin; Héctor J Dueñas
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-04-06       Impact factor: 2.576

10.  Atomoxetine: a novel treatment for child and adult ADHD.

Authors:  Marcialee Ledbetter
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.